Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HS-10241 in Hepatic Impairment
NCT06823245Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Feb 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of dalmelitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Peak Plasma Concentration and Area under the plasma concentration versus time curve. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
dalmelitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06823245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823245.